Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Novartis in tit-for-tat battle

Posted 7 May 2021 AM

The Novartis federal court case over its blockbuster multiple sclerosis drug Gilenya has turned into a tit-for-tat battle with Pharmacor, which is intent on selling a generic version of the drug, filing a cross claim.

Pharmacor asserts the patents for Gilenya are invalid for lack of novelty, lack of inventive step and lack of best method and are liable to be revoked, according to Lawyerly.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options